Colchicine Plus Phenolic Monoterpenes to Treat COVID-19

Mostafaie et al., ClinicalTrials.gov, NCT04392141, NCT04392141

Apr 2021

Source PDF All Studies Meta AnalysisMeta

RCT with 60 patients treated with colchicine and phenolic monoterpenes and 60 control patients in Iran, showing lower mortality with treatment. NCT04392141 (history).

Important missing comments or errors? Let us know.

risk of death, 83.3% lower, RR 0.17, p = 0.11, treatment 1 of 60 (1.7%), control 6 of 60 (10.0%), NNT 12, primary outcome.

hospitalization time, 34.7% lower, relative time 0.65, p < 0.001, treatment 59, control 54.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Mostafaie et al., 20 Apr 2021, Randomized Controlled Trial, Iran, preprint, 1 author, study period 1 April, 2020 - 1 November, 2020, dosage not specified, this trial uses multiple treatments in the treatment arm (combined with phenolic monoterpenes) - results of individual treatments may vary, trial NCT04392141 (history).

All Studies Meta Analysis Submit Updates or Corrections

This Paper Colchicine All

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

@CovidAnalysis

FAQ

Public domain CC0 1.0